Hemlibra is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Emicizumab.
| Product ID | 50242-921_10a84bba-6ac6-4a54-9c2b-55d39a232d59 | 
| NDC | 50242-921 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Hemlibra | 
| Generic Name | Emicizumab | 
| Dosage Form | Injection, Solution | 
| Route of Administration | SUBCUTANEOUS | 
| Marketing Start Date | 2017-11-16 | 
| Marketing Category | BLA / BLA | 
| Application Number | BLA761083 | 
| Labeler Name | Genentech, Inc. | 
| Substance Name | EMICIZUMAB | 
| Active Ingredient Strength | 150 mg/mL | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2020-12-31 | 
| Marketing Start Date | 2017-11-16 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | BLA | 
| Application Number | BLA761083 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | ML | 
| Marketing Start Date | 2017-11-16 | 
| Ingredient | Strength | 
|---|---|
| EMICIZUMAB | 150 mg/mL | 
| SPL SET ID: | 2483adba-fab6-4d1b-96c5-c195577ed071 | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 50242-920 | Hemlibra | emicizumab | 
| 50242-921 | Hemlibra | emicizumab | 
| 50242-922 | Hemlibra | emicizumab | 
| 50242-923 | Hemlibra | emicizumab | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() HEMLIBRA  87449931  5722898 Live/Registered  | 
        CHUGAI SEIYAKU KABUSHIKI KAISHA  2017-05-15  | 
![]() HEMLIBRA  86652355  4892349 Live/Registered  | 
        CHUGAI SEIYAKU KABUSHIKI KAISHA  2015-06-04  |